Dr. George is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2525 Chicago Ave
Minneapolis, MN 55404Phone+1 612-813-6295Fax+1 612-624-8176
Education & Training
- University of Iowa Hospitals and ClinicsFellowship, Neonatal-Perinatal Medicine, 1994 - 1997
- University of Iowa Hospitals and ClinicsResidency, Pediatrics, 1991 - 1994
- Indiana University School of MedicineClass of 1991
Certifications & Licensure
- MN State Medical License 2007 - 2025
- WI State Medical License 2020 - 2025
- IA State Medical License 1991 - 2008
- CO State Medical License 1997 - 1999
- American Board of Pediatrics Neonatal-Perinatal Medicine
Publications & Presentations
PubMed
- 6 citationsAssociation between Term Equivalent Brain Magnetic Resonance Imaging and 2-Year Outcomes in Extremely Preterm Infants: A Report from the Preterm Erythropoietin Neuropr...Dennis E. Mayock, Semsa Gogcu, Mihai Puia-Dumitrescu, Dennis W. W. Shaw, Jason N. Wright
The Journal of Pediatrics. 2021-08-26 - 14 citationsLasting Legacy: Maternal Perspectives of Perinatal Palliative CareHeidi Kamrath, Erin A. Osterholm, Rachael Stover-Haney, Thomas N. George, Susan O'Connor-Von
Journal of Palliative Medicine. 2019-02-22 - 12 citationsDifferences in the Tensor Veli Palatini Between Adults With and Without Cleft Palate Using High-Resolution 3-Dimensional Magnetic Resonance Imaging.Thomas N. George, Katelyn J. Kotlarek, David P. Kuehn, Bradley P. Sutton, Jamie L. Perry
The Cleft Palate-Craniofacial Journal. 2018-01-23
Lectures
- NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: